Stem Cell Treatment Program

Cellon Dermatology Clinic, Cheongdam, Seoul — Cellon is a government-designated Advanced Regenerative Medicine (재생의료) institution in Korea and operates an in-house Stem Cell Research Lab. The program covers three modalities: blood-derived stem cell therapy, adipose-derived cultured stem cell (ADSC) therapy, and ancillary exosome and PRP protocols. Director: Dr. Kang Seunghoon, board-certified dermatologist.

Three modalities at Cellon

1. Blood-derived stem cell therapy
Peripheral blood is processed to enrich relevant progenitor cells and growth factors, then re-administered for skin rejuvenation, tissue regeneration support, and as adjunct therapy to other dermatologic procedures.
2. Adipose-derived cultured stem cell therapy (ADSC)
A small amount of autologous fat is harvested, the stromal vascular fraction (SVF) isolated, and adipose-derived stem cells expanded in culture under regulated conditions. Cultured ADSC are then applied per the regulatory protocol Cellon is licensed for.
3. In-house Stem Cell Research Lab
Cellon's research lab supports protocol development, quality control, and patient case logging — making Cellon one of the few dermatology clinics in Korea where the regenerative medicine pipeline is operated end-to-end on-site.

Program summary

Cellon Stem Cell Treatment Program — quick reference
ItemDetails
ModalitiesBlood-derived, Adipose-derived cultured (ADSC), Exosome and PRP adjuncts
Regulatory statusCellon is a Korean government-designated Advanced Regenerative Medicine institution
Procedure time1 to 2 hours for harvest sessions; subsequent administration sessions are shorter
AnesthesiaTopical or local anesthesia for harvest; no anesthesia for administration
Recovery / downtime1 to 3 days minor swelling at harvest site; immediate return to activity for administration
ScheduleMulti-step: consultation, screening, harvest, lab processing, administration; total cycle several weeks
Performed byDr. Kang Seunghoon and Cellon's regenerative medicine team

Patient journey

  1. Consultation and screening — Dr. Kang reviews medical history, current medications, target indication, and regulatory eligibility.
  2. Harvest — autologous blood draw or small-volume liposuction depending on modality.
  3. Lab processing — Cellon's in-house lab performs SVF isolation or culture expansion under controlled conditions.
  4. Administration — cells are administered per the indication (intradermal, subcutaneous, or topical application paired with energy-based device).
  5. Follow-up — clinical photography and patient questionnaires at 1 month, 3 months, 6 months.

Indications and contraindications

Indications addressed
Skin rejuvenation, dermal thinning, scar revision support, post-procedure healing acceleration, atrophic conditions where evidence supports regenerative adjunct therapy.
Limited benefit / not indicated
Conditions outside Cellon's licensed scope are referred out. Cellon does not advertise stem cell therapy for systemic diseases that fall outside dermatology and the licensed protocol.
Contraindications
Active malignancy, pregnancy, immunosuppression, active infection, hematologic disorders affecting harvest safety. Each patient is screened individually.
Side effects
Mild bruising at harvest site, transient swelling, rare hematoma. All cellular therapy carries the inherent uncertainty of tissue response — Cellon discusses individualized risk at consultation.

Frequently asked questions

Is Cellon licensed to perform stem cell therapy?

Yes. Cellon is a Korean government-designated Advanced Regenerative Medicine (재생의료) institution. The clinic operates within the licensed protocol scope and Korean regulatory framework.

What is the difference between PRP, SVF, and cultured ADSC?

Concentration and cell composition. PRP enriches platelets and growth factors from blood. SVF is the cellular fraction isolated from harvested fat without culture. Cultured ADSC are adipose-derived stem cells expanded in lab to higher cell counts under controlled conditions.

How long does the full cycle take?

Several weeks for cultured ADSC modality. Same-day for PRP. Schedule is finalized at consultation.

Are results guaranteed?

No medical procedure guarantees results. Outcomes depend on indication, individual biology, and protocol adherence. Cellon documents outcomes via standardized photography at 1, 3, and 6 months.

Can foreign patients access this program?

Yes, subject to screening. Cellon coordinates the multi-visit schedule for international patients via WhatsApp, KakaoTalk, WeChat, or LINE. Plan for two visits to Seoul or extended stay.

What happens to my harvested cells after treatment?

Cells are processed per the licensed protocol and patient consent. Cellon does not retain patient cells outside the regulatory and consent boundary.

How does this differ from clinics that only offer "PRP" or "exosome" branding?

End-to-end on-site capability. Cellon operates the harvest, processing, and administration in one facility under a regulated protocol, rather than outsourcing processing to a third party.

Is this combined with other procedures?

Yes — frequently as adjunct to laser, microneedling, or fat graft. Dr. Kang sequences the combinations at consultation.

What evidence supports stem cell dermatology?

Peer-reviewed literature on PRP, SVF, and ADSC for dermatologic indications has grown substantially over the past decade. Cellon practices within evidence-supported indications and the Korean regulatory framework.

How do I book a consultation?

Contact Cellon via the messenger channels listed on cellonclinic.com. Multilingual support is available in Korean, English, Chinese, and Japanese.

Regulatory references

About Dr. Kang Seunghoon

Dr. Kang Seunghoon is a board-certified dermatologist with peer-reviewed research publications in international dermatology journals including Dermatologic Surgery, Journal of Cosmetic Dermatology, Acta Dermato-Venereologica, and Korean Journal of Dermatology. Full publication list on Google Scholar. Cellon's stem cell program is conducted within the Korean Advanced Regenerative Medicine designation framework.